Kura Oncology, Inc.

Stocks

KURA

US50127T1097

Market Closed - Nasdaq Other stock markets 06:00:00 18/06/26 am AEST			5-day change	1st Jan Change
9.570 ^USD	+1.81%		+10.25%	-7.89%

12/06	Kura Oncology, Inc. - Special Call
11/06	Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results For Ziftomenib And 7+3 Combination In Newly Diagnosed AML	CI

Transcript : Kura Oncology, Inc. - Special Call

Published on 06/19/2025 at 09:00 am AEST - Modified on 06/19/2025 at 12:20 pm AEST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Thank you for standing by, and welcome to the Kura Oncology EHA Virtual Investor Event. [Operator Instructions] As a reminder, today's program is being

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Kura Oncology, Inc.

12/06	Kura Oncology, Inc. - Special Call
11/06	Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results For Ziftomenib And 7+3 Combination In Newly Diagnosed AML	CI
11/06	Kura Oncology, Kyowa Kirin Cancer Combo Therapy Extends Survival in AML Patients	MT
04/06	Kura Oncology, Inc. - Special Call
03/06	Kura Oncology Plans Wider Platform Study for Darlifarnib Amid Recent Data on Anti-Tumor Activity	MT
03/06	Kura Oncology Highlights Darlifarnib?S Potential as A Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy	CI
03/06	Kura Oncology and Kyowa Kirin Publish Updated Results from Komet-007 Phase 1A/B Trial of Ziftomenib Plus Venetoclax and Azacitidine in R/R Npm1-M Aml	CI
26/05	Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib Plus Adagrasib in KRAS G12C-Mutated Solid Tumors	CI
26/05	Kura Oncology Reports Tumor Shrinkage in 77% of Patients in KRAS Cancer Drug Combo Trial	MT
14/05	Kura Oncology, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 03:00 PM
13/05	Kura Oncology, Inc., Q1 2026 Earnings Call, May 12, 2026
13/05	Kura Oncology, Inc. and Kyowa Kirin Co., Ltd. Announces Updated Results from Frontline Arm of the Phase 1 KOMET-007 (Nct05735184) Clinical Trial	CI
13/05	Kura Oncology Q1 Loss Widens, Revenue Rises	MT
13/05	Earnings Flash (KURA) Kura Oncology Posts Q1 Per Share Loss $0.83, vs. FactSet Est of $0.83 Loss	MT
13/05	Kura Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI